SOTIO Biotech a.s. has exercised its first of five exclusive, target-specific options for antibody-drug conjugate (ADC) SOT106 under its agreement with LegoChem Biosciences Inc.
Tag Archive for: cancer
In a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US.